false
0001356576
0001356576
2025-07-30
2025-07-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): July 30, 2025
Supernus
Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
| Delaware |
001-35518 |
20-2590184 |
(State or other jurisdiction of
incorporation or organization) |
(Commission
File Number) |
(I.R.S.
Employer Identification No.) |
| 9715
Key West Ave |
Rockville |
MD |
20850 |
| (Address
of Principal Executive Offices) |
|
|
(Zip
Code) |
Registrant’s telephone
number, including area code: (301) 838-2500
Not Applicable
(Former name or former address,
if changed since last report.)
Securities registered pursuant to Section 12(b)
of the Exchange Act
| Title of
each class |
Trading Symbol |
Name of each
exchange on which registered |
| Common
Stock, $0.001 par value per share |
SUPN |
The Nasdaq
Stock Market LLC |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 1.01 | Entry into a Material Definitive Agreement. |
As previously disclosed in
the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) by Supernus Pharmaceuticals, Inc.,
a Delaware corporation (the “Supernus”), on June 16, 2025, Supernus entered into an Agreement and Plan of Merger,
dated as of June 13, 2025 (the “Merger Agreement”), with Sage Therapeutics, Inc., a Delaware corporation
(“Company” or “Sage”), and Saphire, Inc., a Delaware corporation and a wholly-owned subsidiary
of Supernus (“Purchaser”). All capitalized terms used herein and not otherwise defined have the meanings given to such
terms in the Merger Agreement.
Pursuant to the Merger Agreement
and in connection with Purchaser’s acceptance of Shares tendered in the Offer for purchase, on July 30, 2025 the Company and
Equiniti Trust Company, LLC, as rights agent, entered into a contingent value rights agreement (the “CVR Agreement”)
to allow for the payment of the milestones payment(s) pursuant to each CVR (as defined below).
One milestone payment of $0.50
per CVR, net to the seller in cash, subject to any withholding of taxes and without interest, is payable (subject to certain terms and
conditions) upon the first commercial sale after Regulatory Approval (as defined in the CVR Agreement) in Japan to a third-party customer
of the pharmaceutical product that is marketed in the United States under the name ZURZUVAE and is the subject of the current regulatory
filing (including any amended filings based thereon) by Shionogi & Co., Ltd., inclusive of its affiliates, in Japan for
Major Depressive Disorder by June 30, 2026.
A second milestone payment
of $1.00 per CVR, net to the seller in cash, subject to any withholding of taxes and without interest, is payable (subject to certain
terms and conditions) if Net Sales (as defined in the CVR Agreement) of ZURZUVAE are equal to or exceed $250 million in the United States
during a calendar year on or prior to December 31, 2027.
A third milestone payment
of $1.00 per CVR, net to the seller in cash, subject to any withholding of taxes and without interest, is payable (subject to certain
terms and conditions) if Net Sales (as defined in the CVR Agreement) of ZURZUVAE are equal to or exceed $300 million in the U.S. during
a calendar year on or prior to December 31, 2028.
A fourth milestone payment
of $1.00 per CVR, net to the seller in cash, subject to any withholding of taxes and without interest, is payable (subject to certain
terms and conditions) if Net Sales (as defined in the CVR Agreement) of ZURZUVAE are equal to or exceed $375 million in the U.S. during
a calendar year on or prior to December 31, 2030.
Each milestone may only be
achieved once. The maximum amount payable with respect to the CVR issued in respect to each Share is $3.50 in the aggregate. The maximum
amount payable with respect to all the CVRs issued is approximately $234 million. There can be no assurance any payments will be made
with respect to any CVR. It is possible that no milestone is achieved and no payment is made with respect to the CVRs.
The foregoing description
of the CVR Agreement and the CVRs established thereby does not purport to be complete and is qualified in its entirety by reference to
the CVR Agreement, which is filed as Exhibit 10.1 hereto and which is incorporated herein by reference.
| Item 2.01 | Completion of Acquisition or Disposition of Assets. |
Pursuant to the Merger Agreement,
on July 2, 2025, Purchaser commenced a tender offer to purchase all of the outstanding shares of common stock of Sage, par value
$0.0001 per share (the “Shares”), at a price of (i) $8.50 per Share, in cash, less any applicable withholding
taxes and without interest (the “Closing Amount”), plus (ii) one contingent value right per Share (a “CVR”),
which represents the right to receive contingent payments of up to $3.50 per Share, in cash, less any applicable withholding taxes and
without interest, which amount will become payable, if at all, if specified milestones are achieved prior to June 30, 2026, December 31,
2027, December 31, 2028 and December 31, 2030, as applicable, pursuant to the CVR Agreement (collectively, the Closing Amount
plus one CVR, the “Offer Price”), upon the terms and subject to the conditions set forth in the Offer to Purchase,
dated July 2, 2025 (together with any amendments, supplements or modifications thereto, the “Offer to Purchase”),
and in the related Letter of Transmittal (together with any amendments, supplements, or modifications thereto, the “Letter of
Transmittal” and, together with the Offer to Purchase, the “Offer”).
The Offer and related withdrawal
rights expired one minute following 11:59 p.m., Eastern Time, on July 30, 2025 (the “Expiration Date”). Equiniti Trust
Company, LLC, in its capacity as the depositary for the Offer, has advised Purchaser that a total of 36,313,509 Shares had been validly tendered
(and not validly withdrawn) pursuant to the Offer prior to the Expiration Date, representing approximately 58% of the outstanding Shares
as of the Expiration Date. Accordingly, the Minimum Condition has been satisfied.
As a result of the satisfaction
of the Minimum Condition and each of the other conditions to the Offer, effective as of the time on which the Offer expired on the Expiration
Date, Purchaser irrevocably accepted for payment all Shares that were validly tendered (and not validly withdrawn) pursuant to the Offer,
and will, as promptly as practicable thereafter, pay for all such validly tendered Shares.
Following the consummation
of the Offer, the remaining conditions to the Merger (as defined below) set forth in the Merger Agreement were satisfied, and on July 31,
2025, Purchaser was merged with and into Sage without a vote of the stockholders of Sage (the “Merger”) in accordance
with Section 251(h) of the General Corporation Law of the State of Delaware, with Sage surviving the Merger as a wholly owned
subsidiary of Supernus.
At the effective time of the
Merger (the “Effective Time”), each then issued and outstanding Share not previously purchased in the Offer (other
than certain excluded Shares as described in the Merger Agreement) was converted into the right to receive the Offer Price.
Pursuant to the Merger Agreement,
at the Effective Time:
| ● | Each Company Option that was outstanding and
unexercised, whether or not vested, and which had a per Share exercise price that was less than the Closing Amount (each, an “In
the Money Option”), was deemed fully vested and cancelled and converted into the right to receive a cash payment (without interest)
equal to the product of the excess of the Closing Amount over the per Share exercise price of the In the Money Option, multiplied by the
total number of Shares subject to the In the Money Option immediately prior to the Effective Time, which is payable in accordance with
the Merger Agreement and one CVR for each Share subject to the In the Money Option immediately prior to the Effective Time, which is calculated
and payable in accordance with the CVR Agreement. |
| ● | Each Company Option, whether or not vested, that
had a per Share exercise price equal to or greater than $8.50 was cancelled without payment. |
| ● | Each then outstanding Company RSU was deemed
fully vested and cancelled and converted into the right to receive a cash payment (without interest) equal to the product of the Closing
Amount multiplied by the number of Shares subject to the Company RSU, which is payable in accordance with the Merger Agreement and one
CVR for each Share subject to the Company RSU immediately prior to the Effective Time, which is calculated and payable in accordance with
the CVR Agreement. |
| ● | Each Company PSU that was vested (or any portion
thereof) in accordance with its terms and outstanding immediately prior to the Effective Time was cancelled and converted into the right
to receive a cash payment (without interest) equal to the product of the Closing Amount multiplied by the number of Shares subject to
the Company PSU, which is payable in accordance with the Merger Agreement and one CVR for each Share subject to the Company PSU, which
is calculated and payable in accordance with the CVR Agreement. |
| ● | Each then outstanding Company PSU for which the
applicable performance period has not been completed or milestone performance metric, in each case, as set forth in the applicable governing
plan and/or award agreement, has not been achieved, in each case, as of the Effective Time (or any portion thereof) was deemed vested
pursuant to the terms of the Merger Agreement and cancelled and converted into the right to receive a cash payment (without interest)
equal to the product of the Closing Amount multiplied by the number of Shares subject to the Company PSU after giving effect to the agreed-upon
vesting, which is payable in accordance with the Merger Agreement and one CVR for each Share subject to such Company PSU after giving
effect to the agreed-upon vesting, which is calculated and payable in accordance with the CVR Agreement. |
The aggregate consideration
to be paid by Purchaser to complete the Offer and the Merger is approximately $561 million (exclusive of amounts that may be payable
pursuant to the CVRs), without giving effect to related transaction fees and expenses.
The foregoing description
of the Merger Agreement, the Offer and the Merger does not purport to be complete and is qualified in its entirety by reference to the
Merger Agreement, which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by Supernus on June 16, 2025,
and is incorporated herein by reference.
On July 31, 2025, Supernus
issued a press release announcing the successful completion of its acquisition of Sage, including the completion of both the Offer and
the Merger. A copy of the press release is filed as Exhibit 99.1 hereto, and the text of such press release is incorporated herein
by reference.
Forward-Looking Statements
This filing includes forward-looking
statements. These statements do not convey historical information but relate to predicted or potential future events that are based upon
management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. In addition to the factors mentioned in this filing, such risks and uncertainties
include, but are not limited to, Supernus’ ability to sustain and increase its profitability; Supernus’ ability to raise sufficient
capital to fully implement its corporate strategy; the implementation of Supernus’ corporate strategy; Supernus’ future financial
performance and projected expenditures; Supernus’ ability to increase the number of prescriptions written for each of its products,
the products of its subsidiaries and products acquired through the acquisition of Sage; Supernus’ ability to increase its net revenue
from its products, the products of its subsidiaries and products acquired through the acquisition of Sage; Supernus’ ability to
commercialize its products, the products of its subsidiaries and products acquired through the acquisition of Sage; Supernus’ ability
to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies;
Supernus’ product research and development activities, including the timing and progress of Supernus’ clinical trials, and
projected expenditures; Supernus’ ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize
Supernus’ product candidates; Supernus’ ability to protect its intellectual property and the intellectual property of its
subsidiaries and operate its business without infringing upon the intellectual property rights of others; Supernus’ expectations
regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of Supernus’ product
candidates; the accuracy of Supernus’ estimates of the size and characteristics of the markets that may be addressed by its product
candidates; Supernus’ ability to increase its manufacturing capabilities for its products and product candidates; Supernus’
projected markets and growth in markets; Supernus’ product formulations and patient needs and potential funding sources; Supernus’
staffing needs; and other risk factors set forth from time to time in Supernus’ filings with the Securities and Exchange Commission
made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Supernus undertakes no obligation to
update the information in this filing to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated
or unanticipated events.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit 2.1* — Agreement and Plan of Merger, dated as of June 13, 2025, by and among Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc. and Saphire, Inc (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Supernus Pharmaceuticals, Inc. on June 16, 2025).
Exhibit 10.1 — Contingent Value Rights Agreement, dated as of July 30, 2025, by and among Supernus Pharmaceuticals, Inc. and Equiniti Trust Company, LLC
Exhibit 99.1 — Press Release of Supernus Pharmaceuticals, Inc. dated July 31, 2025.
Exhibit 104 — The cover page from
this Current Report on Form 8-K, formatted in Inline XBRL.
Certain financial statements required by Item 9.01 of Form 8-K
are not yet available and will be filed by amendment to this Current Report on Form 8-K no later than 71 calendar days after the
date that this Current Report on Form 8-K is required to be filed.
* Scheduled omitted pursuant to Item 601 of Regulation S-K.
Supernus agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
SUPERNUS PHARMACEUTICALS, INC. |
| |
|
| DATED: July 31, 2025 |
By: |
/s/
Timothy C. Dec |
| |
|
Timothy C. Dec |
| |
|
Senior Vice President and Chief Financial Officer |
